| Literature DB >> 12914679 |
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with an unknown etiology. Pathologic processes implicated in AD include b-amyloid-induced synaptic failure; tau hyperphosphorylation; inflammation; oxidative stress; abnormal neurotransmission involving acetylcholine, glutamate, norepinephrine, serotonin, and dopamine; and abnormalities in second messengers, protein kinases, and apoptosis. Although each of these pathways offers potential therapeutic targets, pharmacologic manipulation of the glutamatergic N-methyl-D-aspartate receptor pathway, alone or in combination with cholinergic therapies, is emerging as the next promising strategy for the treatment of AD and vascular dementia.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12914679 DOI: 10.1007/s11910-003-0019-8
Source DB: PubMed Journal: Curr Neurol Neurosci Rep ISSN: 1528-4042 Impact factor: 5.081